We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

354 hedge funds and large institutions have $5.9B invested in Amedisys in 2020 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 110 increasing their positions, 134 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 45

10% more capital invested

Capital invested by funds: $5.35B → $5.9B (+$554M)

7% more funds holding

Funds holding: 332354 (+22)

1.58% more ownership

Funds ownership: 90.24%91.82% (+1.6%)

17% less call options, than puts

Call options by funds: $37.7M | Put options by funds: $45.5M

18% less repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 134

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
354
Holders Change
+22
Holders Change %
+6.63%
% of All Funds
7.26%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
69
Increased
110
Reduced
134
Closed
45
Calls
$37.7M
Puts
$45.5M
Net Calls
-$7.74M
Net Calls Change
+$18.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Fuller & Thaler Asset Management
26
Fuller & Thaler Asset Management
California
$55.7M +$6.89M +36,946 +15%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$55.7M -$31.2M -167,387 -37%
Loomis, Sayles & Company
28
Loomis, Sayles & Company
Massachusetts
$48.5M +$3.93M +21,076 +9%
RG
29
Redmile Group
California
$44.9M +$9.06M +48,600 +27%
Charles Schwab
30
Charles Schwab
California
$43.4M -$9.46M -50,734 -19%
Millennium Management
31
Millennium Management
New York
$41.2M +$32.9M +176,359 +562%
PC
32
Polar Capital
United Kingdom
$41.1M +$38.2M +204,567 +7,889%
Axa
33
Axa
France
$37.8M +$3.45M +18,509 +11%
Citadel Advisors
34
Citadel Advisors
Florida
$37.4M +$27.1M +145,381 +338%
Ninety One (UK)
35
Ninety One (UK)
United Kingdom
$37.2M -$23.2M -124,342 -40%
Fidelity Investments
36
Fidelity Investments
Massachusetts
$36.1M +$8.44M +45,232 +33%
CG
37
Carmignac Gestion
France
$33.4M +$31.4M +168,308 New
Goldman Sachs
38
Goldman Sachs
New York
$29.2M +$11M +59,095 +67%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$27.2M +$2.2M +11,800 +9%
Hudson Bay Capital Management
40
Hudson Bay Capital Management
Connecticut
$26.3M +$24.7M +132,500 New
Principal Financial Group
41
Principal Financial Group
Iowa
$24.4M +$4.22M +22,615 +23%
Aberdeen Group
42
Aberdeen Group
United Kingdom
$22.8M +$64.7K +347 +0.3%
AAMU
43
Amundi Asset Management US
Massachusetts
$20.1M -$3.59M -19,241 -16%
N
44
Nuveen
North Carolina
$19.2M -$21.9M -117,563 -55%
EVM
45
Eaton Vance Management
Massachusetts
$18.7M -$2.44M -13,107 -12%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$18.2M -$1.11M -5,969 -6%
AII
47
AGF Investments Inc
Ontario, Canada
$18.2M +$9.64M +51,660 +129%
GLA
48
Great Lakes Advisors
Illinois
$18M -$2.89M -15,477 -15%
RCAMU
49
Rothschild & Co Asset Management US
Connecticut
$17.7M -$26.3M -141,193 -61%
Citigroup
50
Citigroup
New York
$17.5M +$11.3M +60,806 +221%

AMED Hedge Fund Activity: Q2 2020 in Review

354 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2020, worth a combined $5.9B — up 10% from $5.35B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new AMED positions and 45 closed out — a net gain of 24 holders — while 110 added to existing stakes and 134 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $110M. The largest seller was BlackRock, cutting an estimated $90.3M.

  • 354 institutional investors held Amedisys (AMED) as of Q2 2020, up from 332 in Q1 2020.
  • Funds reported $5.9B of Amedisys stock for Q2 2020, up 10% quarter-over-quarter.
  • 69 funds opened new Amedisys positions in Q2 2020 and 45 closed out, a net change of +24 holders.
  • The largest Amedisys buyer in Q2 2020 was Acadian Asset Management, an estimated $110M added.
  • The largest Amedisys seller in Q2 2020 was BlackRock, an estimated $90.3M sold.

Based on aggregated 13F filings for Q2 2020.